Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewGR 103691
说明： Highly selective D3 antagonist
化学名： 4'-Acetyl-N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-[1,1'-biphenyl]-4-carboxamide
生物活性 for GR 103691
A potent and selective dopamine D3 receptor antagonist, with a Ki value of 0.3 nM and > 100- fold selectivity over D2 and D4 sites.
许可信息
Sold with the permission of GlaxoSmithKline
技术数据 for GR 103691
| 分子量 | 485.63 |
| 公式 | C30H35N3O3 |
| 储存 | Store at RT |
| CAS Number | 162408-66-4 |
| Smiles | COC1=CC=CC=C1N1CCN(CCCCNC(=O)C2=CC=C(C=C2)C2=CC=C(C=C2)C(C)=O)CC1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for GR 103691
参考文献 for GR 103691
参考文献是支持产品生物活性的出版物。
Audinot et al (1998) A comparative in vitro and in vivo pharmacological characterization of the novel DA D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J.Pharmacol.Exp.Ther. 287 187 PMID: 9765337
Hurley et al (1996) DA D3 receptors are not involved in the induction of c-fos mRNA by neuroleptic drugs: comparison of the DA D3 receptor antagonist GR 103691 with the typical and atypical neuroleptics. Eur.J.Pharmacol. 318 283 PMID: 9016916
Murray et al (1995) A novel series of arylpiperazines with high affinity and selectivity for the DA D3 receptor. Bioorg.Med.Chem.Lett. 5 219
按标靶查看相关产品
按产品操作查看相关产品
关键词: GR 103691, GR 103691 supplier, selective, D3, antagonists, Dopamine, Receptors, dopaminergic, GR103691, GlaxoSmithKline, GSK, 1109, Tocris Bioscience
5 篇 GR 103691 的引用文献
引用文献是使用了 Tocris 产品的出版物。 GR 103691 的部分引用包括：
Wang et al (2015) A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in DA D2 and D3 receptor agonist-induced autophagy activation. Bone Res 11 2057 PMID: 26649942
Lee et al (2015) DArgic effects on in vitro osteogenesis. Mol Cancer 3 15020 PMID: 26558139
Diaz et al (2014) Moderate Alcohol Exposure during the Rat Equivalent to the Third Trimester of Human Pregnancy Alters Regulation of GABAA Receptor-Mediated Synaptic Transmission by DA in the Basolateral Amygdala. Autophagy 2 46 PMID: 24904907
Clemens and Hochman (2004) Conversion of the modulatory actions of DA on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 24 11337 PMID: 15601940
Chen et al (2006) DA D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J Neurosci 26 2513 PMID: 16510729
GR 103691 的评论
目前没有该产品的评论。 Be the first to review GR 103691 and earn rewards!
Have you used GR 103691?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.